BACKGROUND: We retrospectively compared the 7th and the 8th editions of The American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) TNM classification in the cohort of survival of the patients with esophageal squamous cell carcinoma (ESCC) treated by definitive radiotherapy. METHODS: We included in this study 403 patients with ESCC who underwent radiotherapy or chemoradiotherapy, at a total radiation dose of ≥ 50 Gy with curative intent from 2000 to 2016 at Kindai University Hospital, and who had no distant metastasis (excluding supraclavicular lymph node). The same patient data set was re-staged according to both the 7th and 8th editions of AJCC/UICC TNM classification. RESULTS: For the 7th edition, 5-year overall survival (OS) for stages I, II, III, and IV were 58%, 52%, 22%, and 12%, respectively, which seemed to be separable into two groups (Stages I-II and III-IV). In the 8th edition, corresponding values for stages I, II, III, and IV were 65%, 44%, 34%, and 16%, respectively, which seemed to be separated into three groups (Stage I, II-III, and IV). CONCLUSIONS: The 8th edition of AJCC/UICC TNM classification is a useful predictor of OS among ESCC patients who were treated with definitive radiotherapy.
BACKGROUND: We retrospectively compared the 7th and the 8th editions of The American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) TNM classification in the cohort of survival of the patients with esophageal squamous cell carcinoma (ESCC) treated by definitive radiotherapy. METHODS: We included in this study 403 patients with ESCC who underwent radiotherapy or chemoradiotherapy, at a total radiation dose of ≥ 50 Gy with curative intent from 2000 to 2016 at Kindai University Hospital, and who had no distant metastasis (excluding supraclavicular lymph node). The same patient data set was re-staged according to both the 7th and 8th editions of AJCC/UICC TNM classification. RESULTS: For the 7th edition, 5-year overall survival (OS) for stages I, II, III, and IV were 58%, 52%, 22%, and 12%, respectively, which seemed to be separable into two groups (Stages I-II and III-IV). In the 8th edition, corresponding values for stages I, II, III, and IV were 65%, 44%, 34%, and 16%, respectively, which seemed to be separated into three groups (Stage I, II-III, and IV). CONCLUSIONS: The 8th edition of AJCC/UICC TNM classification is a useful predictor of OS among ESCC patients who were treated with definitive radiotherapy.
Entities:
Keywords:
Esophageal cancer; Radiotherapy; Staging system
Authors: T W Rice; C Apperson-Hansen; L M DiPaola; M E Semple; T E M R Lerut; M B Orringer; L-Q Chen; W L Hofstetter; B M Smithers; V W Rusch; B P L Wijnhoven; K N Chen; A R Davies; X B D'Journo; K A Kesler; J D Luketich; M K Ferguson; J V Räsänen; R van Hillegersberg; W Fang; L Durand; W H Allum; I Cecconello; R J Cerfolio; M Pera; S M Griffin; R Burger; J-F Liu; M S Allen; S Law; T J Watson; G E Darling; W J Scott; A Duranceau; C E Denlinger; P H Schipper; H Ishwaran; E H Blackstone Journal: Dis Esophagus Date: 2016-10 Impact factor: 3.429
Authors: Thomas W Rice; Hemant Ishwaran; Eugene H Blackstone; Wayne L Hofstetter; David P Kelsen; Carolyn Apperson-Hansen Journal: Dis Esophagus Date: 2016-11 Impact factor: 3.429
Authors: Thomas W Rice; Donna M Gress; Deepa T Patil; Wayne L Hofstetter; David P Kelsen; Eugene H Blackstone Journal: CA Cancer J Clin Date: 2017-05-26 Impact factor: 508.702